AQST News

AQST CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 Ready to Announce with Confidence?

AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Anaphylm's FDA Approval Prospects: Levi & Korsinsky

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Pomerantz LLP Highlights Class Action Against Aquestive Therapeutics, Inc. – AQST

AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST

Pomerantz LLP Calls Attention to Class Action Involving Aquestive Therapeutics, Inc. – AQST

AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!